Point-of-Care Glucose Testing Market Size
| Study Period | 2019 - 2030 |
| Market Size (2025) | USD 3.58 Billion |
| Market Size (2030) | USD 4.42 Billion |
| CAGR (2025 - 2030) | 4.33% |
| Fastest Growing Market | Asia Pacific |
| Largest Market | North America |
| Market Concentration | Medium |
Major Players*Disclaimer: Major Players sorted in no particular order |
Point-of-Care Glucose Testing Market Analysis
The Point-of-Care Glucose Testing Market size is estimated at USD 3.58 billion in 2025, and is expected to reach USD 4.42 billion by 2030, at a CAGR of 4.33% during the forecast period (2025-2030).
Point-of-care glucose testing has emerged as a pivotal component in the management and diagnosis of diabetes, offering rapid and accessible diagnostic solutions directly at the patient's location.
The global diabetes prevalence is expected to rise significantly, with projections from the International Diabetes Federation (IDF) indicating that by 2045, approximately 783 million adults, or 1 in 8, will be living with diabetes. This increase of 46% underscores the urgent need for efficient and accessible diagnostic tools to manage this chronic condition. The growing incidence of diabetes drives the demand for innovative point-of-care solutions that can provide timely and accurate results, thereby supporting better disease management and improving patient outcomes. A notable innovation in point-of-care testing through collaboration is likely to enhance the market growth. For instance, in July 2023, Avricore Health partnered with Ascensia Diabetes Care to integrate blood glucose monitoring into point-of-care testing. Their joint effort centers on embedding the Contour Next-Gen and Contour Next One BGM systems into Avricore’s HealthTab PCOT platform.
Similarly, a study published in the International Journal of Pharmacy Practice in November 2023 highlights the effectiveness of point-of-care glycated hemoglobin testing. The study demonstrated that community pharmacists in Brazil could identify individuals with pre-diabetes or undiagnosed T2D, facilitating early referral to appropriate treatment services. This reflects the increasing role of point-of-care testing in preventive care and early diagnosis, which can potentially reduce the burden on healthcare systems.
Further solidifying the market's potential, Roche's acquisition of LumiraDx's point-of-care technology platform in January 2024 for USD 295 million represents a strategic move to expand its diagnostic capabilities. LumiraDx’s platform, which integrates microfluidic test strips with a portable instrument, allows for the performance of multiple lab-quality tests at the point of care. This versatile device covers a range of tests including coagulation, diabetes, and respiratory viruses, illustrating the broad applications and future potential of point-of-care diagnostics.
The market for point-of-care glucose testing is rapidly evolving, driven by technological innovations and a rising global prevalence of diabetes. As the number of individuals living with diabetes continues to grow, the demand for advanced point-of-care testing solutions is expected to rise, highlighting the importance of ongoing innovation and investment in this critical area of healthcare.
Point-of-Care Glucose Testing Market Trends
The Meters Segment Is Expected To Witness The Significant Growth Over The Forecast Period
The glucose meters segment is poised for substantial growth over the forecast period, fueled by technological advancements and evolving clinical practices. For instance, in November 2023, a study published in Advances in Laboratory Medicine examined the effectiveness of point-of-care (POC) glucometers during oral glucose tolerance tests (OGTT) in pediatric patients. This study revealed that the POC glucometers correlated highly with central laboratory results and significantly reduced turnaround times (TAT), although their diagnostic concordance was not as high as desired. Despite this, clinical decisions based on POC glucometer results matched those from central laboratories 92.8% of the time, underscoring their utility as supportive tools rather than standalone diagnostic instruments. As clinical guidelines recommend, POC glucometers are not yet endorsed for primary diagnosis but remain valuable for assisting central laboratories, particularly in pediatric OGTT scenarios.
Furthermore, a study published in Paediatrics & Child Health Journal in October 2024 highlighted the role of POC testing in managing neonatal hypoglycemia. The study confirmed that POC testing for capillary blood glucose is a widely adopted practice in neonates, specifically those under 72 hours old.
The Canadian Pediatric Society's guidelines recommend intervention for hypoglycemia when blood glucose levels fall below 2.6 mmol/L within the first 72 hours or below 3.3 mmol/L thereafter. This endorsement emphasizes the critical role of glucose meters in early hypoglycemia detection and treatment, which is crucial for neonatal care.
The meters segment is expected to experience significant growth due to advancements in glucose monitoring technology and its expanding applications in clinical settings. As these devices continue to evolve, their integration into standard diagnostic protocols will likely enhance patient outcomes and drive further growth in the meters segment.
North America is Expected to Have the Significant Market Share Over the Forecast Period
The North American market for point-of-care glucose testing (POCT) is anticipated to hold a significant share over the forecast period. This expectation is fueled by the region’s high prevalence of diabetes, innovations in healthcare technology, and strategic partnerships aimed at enhancing diabetes management.
Several factors are driving North America's substantial market share in POCT. One prominent factor is the high prevalence of diabetes in the region. According to the International Diabetes Federation (IDF), the North America and Caribbean (NAC) region has the second highest diabetes prevalence among its regions, with a current rate of 14%. The IDF projects a 24% increase in diabetes cases in the NAC region by 2045, reaching 63 million people. This rising incidence underscores the urgent need for efficient glucose monitoring solutions and supports the growing market for POCT devices.
Recent innovations and strategic partnerships are further propelling market growth. For instance, in July 2024, TELUS, in collaboration with The Alex Community Health Centre and the University of Calgary, launched a pilot program to provide mobile diabetes POCT via The Alex Mobile Care Clinic. This initiative aims to deliver essential glucose testing services directly to vulnerable populations in Calgary, highlighting the increasing accessibility and adoption of POCT in diverse healthcare settings. The program, powered by TELUS Health, represents a significant step towards improving diabetes management and patient care in underserved communities.
Additionally, in August 2024, a notable partnership between Glytec, a diabetes and insulin management software company, and Roche, a pharmaceutical firm, was announced. This collaboration will integrate Glytec's advanced software with Roche's point-of-care smart-device blood glucose system, Cobas pulse, enhancing the capabilities of glucose monitoring both in the United States and globally. This integration reflects a broader trend of leveraging technology to improve the accuracy and efficiency of glucose testing, further boosting the North American market's growth prospects.
The North American point-of-care glucose testing market is set to capture a significant share over the forecast period, driven by the high diabetes prevalence and advancements in POCT technology. The region's proactive initiatives, such as mobile testing programs and strategic industry partnerships, underscore its commitment to improving diabetes care and managing the growing patient population.
Point-of-Care Glucose Testing Industry Overview
The Point-of-Care Glucose Testing Market is fragmented, with a few significant and generic players. Many of these key players operate on a global scale, encountering fierce competition in emerging economies. These nations are turning into battlegrounds for major competition, driven by a swiftly growing market, particularly in home-care point-of-care testing. Manufacturers like Abbott, LifeScan, F. Hoffmann-La Roche AG, and Ascensia have a global market presence and occupy a major share, while the remaining players, such as EKF Diagnostics, are confined to the other local or region-specific manufacturers.
Point-of-Care Glucose Testing Market Leaders
-
Abbott
-
F. Hoffmann-La Roche Ltd
-
LifeScan IP Holdings, LLC
-
Ascensia Diabetes Care Holdings AG
-
ARKRAY, Inc.
- *Disclaimer: Major Players sorted in no particular order
Point-of-Care Glucose Testing Market News
- June 2024: Nova Biomedical has launched its next-generation StatStrip glucose hospital meter system in the United State, following a 510(k) clearance. The upgraded system boasts features such as a Linux operating system for enhanced cybersecurity, RFID data entry, wireless charging capabilities, and a hematocrit range spanning from 5 to 75 percent. Notably, the FDA has cleared the meter for use on critically ill patients.
- April 2024: Roche Diagnostics India's launch of the NT-proBNP test. This test is specifically designed to screen diabetes patients for cardiovascular diseases, including heart failure. Utilizing the NT-proBNP biomarker, available exclusively on the cobas h 232 system, the test promises to offer faster and more efficient management of heart failure in individuals with type 2 diabetes (T2D).
Point-of-Care Glucose Testing Industry Segmentation
POC testing is a widely used tool to enable the immediate determination of glucose levels in hospitalized patients and facilitate rapid treatment decisions in response to fluctuations in glycemia. The Point-of-Care glucose testing market is segmented into product type, testing site, end-user and geography. By product, the market is segmented into lancet and lancing devices, strips, and meters. By testing site, the market is segmented by fingertips and alternative site testing). By end-user, the market is segmented into professional diagnostic centers, hospitals and clinics, home care settings, and others. By Geography, the market is segmented into North America, Europe, Asia-Pacific, Middle East and Africa, and Latin America. The report offers the value (USD) for the above segments.
| By Product Type | Lancet and Lancing Devices | ||
| Strips | |||
| Meters | |||
| By Testing Site | Fingertips | ||
| Alternative Site Testing | |||
| By End-User | Professional Diagnostic Centers | ||
| Hospitals & Clinics | |||
| Home Care Settings | |||
| Others | |||
| Geography | North America | United States | |
| Canada | |||
| Mexico | |||
| Europe | Germany | ||
| United Kingdom | |||
| France | |||
| Italy | |||
| Spain | |||
| Rest of Europe | |||
| Asia-Pacific | China | ||
| Japan | |||
| India | |||
| Australia | |||
| South Korea | |||
| Rest of Asia-Pacific | |||
| Middle East and Africa | GCC | ||
| South Africa | |||
| Rest of Middle East and Africa | |||
| South America | Brazil | ||
| Argentina | |||
| Rest of South America | |||
| Lancet and Lancing Devices |
| Strips |
| Meters |
| Fingertips |
| Alternative Site Testing |
| Professional Diagnostic Centers |
| Hospitals & Clinics |
| Home Care Settings |
| Others |
| North America | United States |
| Canada | |
| Mexico | |
| Europe | Germany |
| United Kingdom | |
| France | |
| Italy | |
| Spain | |
| Rest of Europe | |
| Asia-Pacific | China |
| Japan | |
| India | |
| Australia | |
| South Korea | |
| Rest of Asia-Pacific | |
| Middle East and Africa | GCC |
| South Africa | |
| Rest of Middle East and Africa | |
| South America | Brazil |
| Argentina | |
| Rest of South America |
Point-of-Care Glucose Testing Market Research FAQs
How big is the Point-of-Care Glucose Testing Market?
The Point-of-Care Glucose Testing Market size is expected to reach USD 3.58 billion in 2025 and grow at a CAGR of 4.33% to reach USD 4.42 billion by 2030.
What is the current Point-of-Care Glucose Testing Market size?
In 2025, the Point-of-Care Glucose Testing Market size is expected to reach USD 3.58 billion.
Who are the key players in Point-of-Care Glucose Testing Market?
Abbott, F. Hoffmann-La Roche Ltd, LifeScan IP Holdings, LLC, Ascensia Diabetes Care Holdings AG and ARKRAY, Inc. are the major companies operating in the Point-of-Care Glucose Testing Market.
Which is the fastest growing region in Point-of-Care Glucose Testing Market?
Asia Pacific is estimated to grow at the highest CAGR over the forecast period (2025-2030).
Which region has the biggest share in Point-of-Care Glucose Testing Market?
In 2025, the North America accounts for the largest market share in Point-of-Care Glucose Testing Market.
What years does this Point-of-Care Glucose Testing Market cover, and what was the market size in 2024?
In 2024, the Point-of-Care Glucose Testing Market size was estimated at USD 3.42 billion. The report covers the Point-of-Care Glucose Testing Market historical market size for years: 2019, 2020, 2021, 2022, 2023 and 2024. The report also forecasts the Point-of-Care Glucose Testing Market size for years: 2025, 2026, 2027, 2028, 2029 and 2030.
Point-of-Care Glucose Testing Industry Report
Statistics for the 2025 Point-of-Care Glucose Testing market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. Point-of-Care Glucose Testing analysis includes a market forecast outlook for 2025 to 2030 and historical overview. Get a sample of this industry analysis as a free report PDF download.
